|D009140||Musculoskeletal Diseases NIH||1.00|
|D048909||Diabetes Complications NIH||1.00|
|D019636||Neurodegenerative Diseases NIH||1.00|
There is one clinical trial.
This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.
Description: Proportion, RateMeasure: Incidence of IgG against SARS-CoV-2 Time: one year
Description: TiterMeasure: titration and evolution of humoral response (IgG) along first 12 months after having Covid-19 Time: 12 months
Description: Categoric Yes/NotMeasure: Reinfection of Covid-19 Time: one year
Description: RateMeasure: Mortality Time: 12 months after Covid-19
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports